key: cord-0810335-foovovj8
authors: Rassy, Elie; Khoury‐Abboud, Rita‐Maria; Ibrahim, Nathalie; Assi, Tarek; Samra, Bachar; Hanna, Colette; El Karak, Fadi; Ghosn, Marwan
title: Should we screen patients with hematologic malignancies for COVID‐19?
date: 2020-07-19
journal: Hematol Oncol
DOI: 10.1002/hon.2780
sha: 826dd0dd934e335629543cb33c58c2c1348b795c
doc_id: 810335
cord_uid: foovovj8

The coronavirus disease (COVID‐19) pandemic has posed several challenges to the hematology community to re‐organize the medical care of patients with hematologic malignancies. Whereas the oncology societies favored a more or less conservative approach which considered the possibility of delaying treatment administration on a case‐by‐case basis, the hematology community guidelines were less stringent and recommended adequate individualized regimens. As countries are de‐escalating the lockdown and the medical community is unable to foresee the end of the current outbreak will and whether the pandemic would eventually come back as a seasonal infection, there is interest in screening of patients with hematology malignancies with COVID‐19 instead of limiting access to curative treatments. The rapidly accumulating knowledge about COVID‐19 allows a better understanding of the diagnostic tools that may be potentially used in screening. Herein, we briefly review the pathophysiology of COVID‐19, the rationale of screening of patients with hematologic malignancies, tools for screening, and available guidelines. This article is protected by copyright. All rights reserved.

Just over six months after the first reports of the coronavirus disease in Wuhan, China, the COVID-19 pandemic has become a serious pandemic leading to over three million cases which overloaded the healthcare systems and lead to an alarming figure of death numbers 1 . Since COVID-19 is a novel disease, guidance by scientific evidence is limited and impactful decisions are inevitably based on expert opinions that recommend isolation and quarantine given the highly infectious attribute of the virus. The early reports of patients with COVID-19 showed that higher rates of severe illness occurred in older patients (mean 63.1 vs 48.7 years; p < 0.001), those with a smoking history (22 vs 7%; p = 0.032), and those with cancer (39 vs. 8%; p = 0.0003) 2,3 . In the multivariate analysis, cancer was the highest individual risk factor for severe events (OR = 5.4; 95% CI 1.8-16.2) 3 . As a result, oncologists were challenged to reorganize the oncological care of patients with solid and hematological malignancies without compromising cancer outcomes 4, 5 .

The understanding of the COVID-19 process in patients with solid malignancies is increasing whereas the reports of patients with hematologic malignancies remain scarce. Patients with hematologic malignancies are at increased risk of COVID-19 due to the disease biology and associated therapy. Moreover, the immunocompromised patients with COVID-19 may also be at higher risk of superimposed bacterial or fungal pneumonia 6(p19) . A cohort study on 128 hospitalized patients with hematologic malignancy did not show a higher rate of COVID-19 (10 vs 7%, p = 0.322) but reported a higher death rate (63 vs 0%, p = 0.002) compared to healthy healthcare providers 7 . A recent French observational study reporting on 48 patients with hematological malignancies tested for COVID-19 based on clinical suspicion 8 . Twenty-five patients (of whom 20 had lymphoid malignancy including 10 multiple myeloma patients) tested positive with suggested possible nosocomial infection in 40%, acute respiratory distress syndrome occurred in 52%, and mortality rate at one month was 60% 8 . Consequently, patients with hematologic malignancies are more susceptible to severe forms of COVID-19. As we write this paper, countries are attempting to deescalate the confinement measures, which raise interest in the potential benefit of screening measures for COVID-19 in asymptomatic patients with hematologic malignancies.

The currently available data on the COVID-19 physiopathology point out to a two-phase clinical course for the disease. The first phase occurs within the first days, consists of non-specific symptoms such as fever, fatigue, and diarrhea, and during which the lymphocyte and neutrophil counts seem to remain within the normal ranges 9, 10 . The second phase occurs 7-14 days after symptom appearance, likely corresponding to a second viral lynching, characterized by a cytokine storm responsible for both severe interstitial lung inflammation and extrapulmonary multiorgan damage 11 . During this phase, there is a significant decrease in the B and T lymphocytes that is associated with adverse outcomes 10, 12 . As a result, patients with hematologic malignancies may be particularly at a higher risk of developing COVID-19 for multiple reasons associated with profound and prolonged neutropenia 13, 14 , lymphopenia 15 , the high-dose corticosteroids used in the majority of lymphoma and multiple myeloma regimens, and the frequent and long hospitalization for chemotherapy or transfusions 16 .

At this moment, it is not foreseeable when the current outbreak will end and whether the pandemic would eventually come back as a seasonal infection. To date, there are no evidence-based guidelines for the screening of patients with hematologic malignancies and the recommended measures are based on previous experiences from other infectious diseases. The available data in cancer patients show that those undergoing chemotherapy are at higher risk of severe COVID-19 4 . Moreover, patients with hematologic malignancies have the additional impact of the acquired disease-related secondary immunodeficiency, the common use of corticosteroids in myeloma and lymphoma regimens, and the use of monoclonal antibodies. Other potential considerations for which clear impact has not been yet established include the use of tyrosine kinase inhibitors (TKI) and colonystimulating factors.

The pathophysiology of acquired immunodeficiency in lymphoproliferative disorders is in part inherent to the disease itself. Hematologic malignancies are accompanied by dysfunction in both cellular and humoral immunity, with B cell, T cell, NK cells, and dendritic-cell function, neutropenia due to marrow infiltration, and hypogammaglobulinemia [17] [18] [19] . In patients with CLL, the secretion of TGFβ and high IL2 levels are responsible for B-cell proliferation inhibition and T-helper cell downregulation respectively, partly explaining the resulting various immune deficiencies 18 . In multiple myeloma, reduced levels of uninvolved immunoglobulins are a hallmark of the disease 20 but are not the sole actors of the acquired immunodeficiency in patients. Impaired dendritic cell and NK cell functions, as well as neutropenia and impaired lymphocyte function, are main contributors 17, 21 .

Corticosteroids are a mainstay in the treatment of lymphomas and multiple myelomas however they predictably result in neutrophilic leucocytosis, smaller elevations in monocyte, and reductions in both lymphocytes and eosinophils. Moreover, corticosteroids reduce the ability of leukocytes to adhere to vascular endothelium and exit from the circulation as well as inhibit the phagocytic function, T cell functions, and immunoglobulin production by B cells.

The past experiences with previous coronaviruses show controversial outcomes that limit clear conclusions 22 . The corticosteroid use was associated with a delayed virus clearance from blood and respiratory tract for Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), respectively 23, 24 . However, it was not associated with a statistically significant difference in mortality 25 .

The current evidence for the use of corticosteroids in patients with COVID-19 is limited to small retrospective case series. A retrospective study including 15 patients with COVID-19 pneumonia and requiring intensive care unit hospitalization, hydrocortisone (400 mg daily for a mean 9,5 days) was beneficial in terms of oxygenation but did not improve ICU mortality 26 . A larger retrospective cohort of 46 patients with severe COVID-19 pneumonia found no difference in mortality between the group of 26 patients who received methylprednisone (1-2 mg/kg/day for 5-7 days) and the group not receiving corticoid treatment. Patients treated with methylprednisone had a significantly shorter length of hospital stay, faster oxygenation improvement, and were less likely to require mechanical ventilation 27 . As such, the fifth version of the Chinese National Health Commission treatment scheme for COVID-19 pneumonia includes low dose methylprednisone for 3-5 days in the list of adjuvant treatments 28 .

The available evidence concerning the safety of monoclonal antibodies such as rituximab and ofatumumab (anti-CD20), inotuzumab ozogamycine (anti-CD22), brentuximab vedotin (anti-CD30), and alemtuzumab (anti-CD52) is lacking in patients with/or at risk of COVID-19. However, the labels of these drugs report an increased risk of new viral infections or reactivations. Notably, lymphoma patients receiving rituximab whether alone or in combination with chemotherapy failed to produce effective protective antibody titers after receiving an Influenzae A vaccine 29 . Safety data concerning TKI are also inexistent with reports showing an off-target inhibition of kinases important in B-cell signaling, reduction of memory B-cell frequencies, and impairment of B cell responses in CML patients treated with TKI 30 . For instance, bruton TKI, was associated with an impaired innate immune response as well as B-and T-cell functions 6(p19) . However, a case series of six patients with Waldenstrom macroglobulinemia with COVID-19 did not report on the occurrence of severe cases which was attributed to the shift from an M1-(inflammation promoters) to an M2 (inflammation inhibitors) -polarized macrophage response induced by ibrutinib 31, 32 . Other tyrosine kinase inhibitors such as FLT3 inhibitors (approved in acute myeloid leukemia), PI3K inhibitors (approved in chronic lymphocytic leukemia), and BCL-2 inhibitors (approved in acute myeloid leukemia and chronic lymphocytic leukemia) are known to increase the risk of upper respiratory tract infection and should be avoided if possible [33] [34] [35] . Many other targeted therapies such as proteasome inhibitors and immunomodulatory imide drugs (approved in multiple myeloma), IDH inhibitors (approved in acute myeloid leukemias), and BRAF inhibitors (approved in hairy cell leukemia), lack safety data for COVID-19.

The preclinical data on the use of colony-stimulating factors shows a transient worsening of lymphopenia thought to be controlling viral infections 5 . Clinical evidence has reported cases of worsening lung injury upon the recovery of neutropenia following colony-stimulating factor use mainly due to immune reconstitution 36, 37 . The available evidence concerning the impact of colonystimulating factors in the particular case of patients with COVID-19 is limited to a higher level colonystimulating factors in patients with severe COVID-19 suggesting a potential risk of inflammatory cytokine storm 38 . Nevertheless, the guidelines favor the systematic use of granulocyte colonystimulating factors support to minimize neutropenia risk 28, 39 .

The knowledge of the COVID-19 pathogenesis has led to a better understanding of the COVID-19 diagnostic tests. Three types of diagnostic tests are commonly in use including reverse transcriptasepolymerase chain reaction (RT-PCR), IgM and IgG enzyme-linked immunosorbent assay (ELISA), and chest CT scan 40, 41 . The most commonly used and reliable test is RT-PCR which measures the viral RNA load in the nasopharyngeal swab. The virus is detectable from day 1 on symptoms, peaks within the first week of symptom onset, and declines by week 3 before becoming undetectable. RT-PCR positivity declines more slowly in sputum and stool. A positive test usually presents less than 40 cycle threshold which is the number of replication cycles to produce a fluorescent signal, thus it reflects the detection of viral DNA and does not necessarily indicate the presence of a viable virus 42 . On the other hand, false-negative results were attributed to inaccurate sampling techniques or inappropriate timing of sample collection 40 . Serological testing is mainly important in the diagnosis of patients who present after two weeks of symptom onset. The screening role of this tool encloses the testing of individuals that became immune to the virus especially asymptomatic patients from highly endemic areas 43, 44 . IgM and IgG seroconversion occur as early as the fourth day after symptom onset with higher levels in the second and third week of illness 45 . Last, chest imaging mainly using a chest CT scan was used is some centers to screening for COVID-19. It is widely available, easily performed, and allows a fast diagnosis 19 . Radiologically suggestive features include patchy ground-glass opacities in the two lower lobes bilaterally 46 . Although the available evidence supports a higher sensitivity for chest CT scan over RT-PCR, the American College of Radiology advised against the use of chest CT scan for screening and diagnostic purposes of COVID-19 47, 48 .

The time course of RT-PCR testing positivity, seroconversion, and imaging findings is most probably delayed in patients with hematologic malignancies because of the inherent immunosuppression to their malignancy and to the effect of chemotherapy, targeted therapy, and immunotherapy (as discussed previously). Subsequently, it is elusive to consider that diagnostic testing presents the same pre-and post-test values during the same time course in patients with hematological malignancies. As these tools seem to present a low yield in detecting the virus in asymptomatic patients, it is common sense that their sensitivity would be lower in asymptomatic patients with hematological malignancies 40 .

Given the high transmissibility rate of COVID-19, it is the responsibility of cancer centers to adapt the treatment regimens to reduce the number of hospitalizations and to prevent anticancer treatmentinduced complications of COVID-19 5 . Subsequently, there is more rationale for less intensive but effective therapies that require fewer and shorter hospitalizations over reducing patient access to cancer centers and using therapies with unproven benefit in curable diseases 6 . As a result, international hematology societies have issued their recommendations according to this perspective. Several screening steps have been adopted in several cancer centers in Europe such as calling patients 24 hours before hospital admission to screen for any COVID-19 symptoms and screening them upon arrival to the hospital for COVID-19 symptoms 5 . In the absence of any evocative signs or symptoms, patients can be admitted to the hematology ward where healthcare workers can also be screened weekly for COVID-19. The initial evaluation should include exposure history, clinical examination, basic blood exams, and radiological evaluation preferably using a chest CT scan given that up to 75% of patients at risk of a delayed or missed diagnosis [49] [50] [51] [52] . Testing of caregivers preferably using serologic testing, to ensure the protection of patients and the presence of sufficient qualified personnel has also been suggested 53 .

The European Hematology Association (ESH) and American Hematology Association (ASH) issued screening guidelines in patients with acute leukemias 39, 54 . The ESH guidelines recommend RT-PCR screening in newly diagnosed acute leukemia cases and before every treatment cycle even among asymptomatic patients 54 . The ASH guidelines were less stringent and considered RT-PCR testing all patients for COVID-19 before induction initiation for both acute myeloid and lymphoid leukemias 39 . Both guidelines did not issue any recommendation concerning the screening role of chest CT scan 39, 54 . In patients with chronic myeloid leukemia, ASH did not suggest screening recommendations whereas ESH considered screening all newly diagnosed patients using RT-PCR is ideal but should be discussed depending on test availabilities 39, 54 . In regards to lymphomas and multiple myeloma, the practices differ depending on the prevalence of COVID-19 and the availability of screening but there is not any direct recommendation in this regard 39, 55, 56 . Some centers are beginning to screen patients beginning therapy especially those with Hodgkin's lymphoma because of the concerns for bleomycin-induced lung toxicity which might be problematic during the pandemic 39 .

The European Society for Blood and Marrow Transplantation (ESBMT) and American Society for Transplantation and Cellular Therapy guidelines recommend screening all donors and patients within 72 hours before undergoing conditioning chemotherapy (after patient and donor home isolation for four and two weeks, respectively in the ESBMT guidelines) 57, 58 . Concerning CAR-T cell therapies, experts consider RT-PCR testing within 48-72 hours before apheresis and 48-72 hours before lymphodepleting chemotherapy. Repeat evaluation of RT-PCR within 72 hours of CAR-T cell infusion to detect interim COVID-19 and perform serologic testing for COVID-19 seroconversion once available 59, 60 .

The management of patients with hematologic malignancies during the COVID-19 pandemic may be challenging. By reviewing the pathogenesis of hematologic malignancies and the impact of chemotherapy and steroids, we have shown that patients with hematologic malignancies are undoubtedly a very vulnerable population to COVID-19. These patients present profound and prolonged neutropenia and lymphopenia especially following intensive chemotherapy leading lo frequent and long hospitalizations. In addition, the available evidence, mainly some preclinical data, alludes to an immune dysregulation from targeted therapies that may increase the risk for COVID-19 but the clinical data is lacking. We believe that optimal preventive measures, mainly social distancing, reduces the risk of COVID-19. However, the severity of COVID-19 in patients with hematologic malignancies remains considerable. Efforts to keep hematology departments COVID-19 free zones should be prioritized by screening the staff and the patients as well as limiting patient visits. We have previously proposed, in addition to other international societies, a screening strategy for COVID-19 according to a risk-level based on management 19 . Unfortunately, solid scientific data are lacking on how to screen patients for COVID-19 with all the discussed limitations of RT-PCR and serologic testing. Whereas the international hematology community has shared and discussed expert opinions that provide the roadmap in the short term, the oncology community should close the large knowledge gap in screening for COVID-19 to enable evidence-based algorithms and ensure the safe management of patients with hematologic malignancies. 

Live): 3,515,743 Cases and 245,617 Deaths from COVID-19 Virus Pandemic -Worldometer

Clinical Characteristics of Coronavirus Disease 2019 in China

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

What the oncologist needs to know about COVID-19 infection in cancer patients

Caring for patients with cancer in the COVID-19 era

Treating Leukemia in the Time of COVID-19

COVID-19 in persons with haematological cancers

COVID-19 outcomes in patients with hematologic disease

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Clinical observation and management of COVID-19 patients

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

COVID-19, ECMO, and lymphopenia: a word of caution

Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer Off J Multinatl Assoc Support Care Cancer

Lymphopenia a simple prognostic factor in lymphoma and other cancers: why not use it more as a guide?

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Secondary immunodeficiency in lymphoproliferative malignancies

Immune defects in patients with chronic lymphocytic leukemia

Screening strategies for COVID-19 in patients with hematologic malignancies

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma

Immunodeficiency and immunotherapy in multiple myeloma

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

SARS: systematic review of treatment effects

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia

A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia

ESMO management and treatment adapted recommendations in the COVID-19 era: Diffuse large B-cell lymphoma, Mantle cell lymphoma and Aggressive T-cell lymphomas

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Exacerbation with granulocyte colony-stimulating factor of prior acute lung injury during neutropenia recovery in rats

Recombinant granulocyte colony-stimulating factor (G-CSF) in infectious diseases: still a debate

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients

COVID-19 Resources

Interpreting Diagnostic Tests for SARS-CoV-2

Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR

Virological assessment of hospitalized patients with COVID-2019

Place des tests sérologiques dans la stratégie de prise en charge de la maladie COVID-19. Haute Autorité de Santé

Information for Laboratories about Coronavirus (COVID-19)

Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv

Chest CT and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date

Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis

ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. ACR website. www.acr.org/ Advocacy-and-Economics/ACR-Position-Statements/ Recommendations-for-Chest-Radiography-and-CTfor-Suspected-COVID19-Infection

The clinical significance and management of fever in acute myelocytic leukemia

ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus

BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation

Acute leukemia in the time of COVID-19

What to expect: Oncology's response to coronavirus in Italy -ecancer

Recommendations for specific hematologic malignancies

Multiple Myeloma in the Time of COVID-19

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma

EBMT Recommendation on: CORONAVIRUS DISEASE COVID-19: EBMT; 2020

COVID-19 Resource Community -ASTCT. Accessed

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic